These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 30088950)

  • 1. Making IVF more effective through the evolution of prediction models: is prognosis the missing piece of the puzzle?
    Simopoulou M; Sfakianoudis K; Antoniou N; Maziotis E; Rapani A; Bakas P; Anifandis G; Kalampokas T; Bolaris S; Pantou A; Pantos K; Koutsilieris M
    Syst Biol Reprod Med; 2018 Oct; 64(5):305-323. PubMed ID: 30088950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elective single embryo transfer following in vitro fertilization.
    Min JK; Hughes E; Young D; ;
    J Obstet Gynaecol Can; 2010 Apr; 32(4):363-377. PubMed ID: 20500945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal serum concentration of anti-Müllerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment.
    Sadruddin S; Barnett B; Ku L; Havemann D; Mucowski S; Herrington R; Burggren W
    PLoS One; 2020; 15(10):e0239779. PubMed ID: 33044971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of antral follicle count and serum anti-Müllerian hormone: Which is better for live birth prediction in patients aged over 40 with their first IVF treatment?
    Lee Y; Kim TH; Park JK; Eum JH; Lee HJ; Kim J; Lyu SW; Kim YS; Lee WS; Yoon TK
    Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():151-155. PubMed ID: 29306180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH.
    Gleicher N; Kushnir VA; Sen A; Darmon SK; Weghofer A; Wu YG; Wang Q; Zhang L; Albertini DF; Barad DH
    J Transl Med; 2016 Jun; 14(1):172. PubMed ID: 27286817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive values of anti-müllerian hormone, antral follicle count and ovarian response prediction index (ORPI) for assisted reproductive technology outcomes.
    Ashrafi M; Hemat M; Arabipoor A; Salman Yazdi R; Bahman-Abadi A; Cheraghi R
    J Obstet Gynaecol; 2017 Jan; 37(1):82-88. PubMed ID: 27976974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing four ovarian reserve markers--associations with ovarian response and live births after assisted reproduction.
    Brodin T; Hadziosmanovic N; Berglund L; Olovsson M; Holte J
    Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1056-63. PubMed ID: 26184379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice.
    La Marca A; Sunkara SK
    Hum Reprod Update; 2014; 20(1):124-40. PubMed ID: 24077980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
    Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
    Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of anti-Müllerian hormone in predicting pregnant outcomes of polycystic ovary syndrome patients undergone assisted reproductive technology].
    Li Y; Tan JQ; Mai ZY; Yang DZ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jan; 53(1):23-30. PubMed ID: 29374882
    [No Abstract]   [Full Text] [Related]  

  • 17. Do female age and body weight modify the effect of individualized FSH dosing in IVF/ICSI treatment? A secondary analysis of the OPTIMIST trial.
    Leijdekkers JA; van Tilborg TC; Torrance HL; Oudshoorn SC; Brinkhuis EA; Koks CAM; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Broekmans FJM; Eijkemans MJC;
    Acta Obstet Gynecol Scand; 2019 Oct; 98(10):1332-1340. PubMed ID: 31127607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
    Majumder K; Gelbaya TA; Laing I; Nardo LG
    Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):166-70. PubMed ID: 20223579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified natural cycle versus controlled ovarian hyperstimulation IVF: a cost-effectiveness evaluation of three simulated treatment scenarios.
    Groen H; Tonch N; Simons AH; van der Veen F; Hoek A; Land JA
    Hum Reprod; 2013 Dec; 28(12):3236-46. PubMed ID: 24166594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.